As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house executive to lead the surge. | Suarez will return to the U.S. as SVP and ...
It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...
In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...
InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...
Less than two weeks ago, Vanda scored an FDA approval for motion sickness pill Nereus. The decision came 15 months after the ...
Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA ...
Novo took its message to the people by setting up an exhibit at New York’s Grand Central Terminal. In a major thoroughfare at ...
Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug ...
The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for ...
Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...
Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma ...
Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback